SOLUBILITY EVALUATIONS OF OSIMERTINIB MESYLATE IN PHYSIOLOGICAL BUFFERS

被引:8
作者
Al-Shahrani, Saad [1 ]
Ansari, Mohammad Javed [1 ]
机构
[1] Prince Sattam Bin Abdul Aziz Univ, Coll Pharm, Dept Pharmaceut, Al Kharj, Saudi Arabia
来源
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2018年 / 5卷 / 04期
关键词
Osimertinib mesylate; absorption; Solubility; physiological buffers;
D O I
10.5281/zenodo.1220226
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Limited water solubility of drugs is a prevailing problem to efficient drug delivery as a huge proportion of available drugs are poorly water soluble. Poorly soluble drugs suffer with low or incomplete oral absorptions leading to low or variable bioavalibilities. Osimertinib mesylate is a novel anticancer drug for the treatment of lung cancer. It is reported to have low absorption and exposure at therapeutic doses of 80 mg which could be due to low solubility in gastrointestinal tract. It is important to evaluate pH solubility profile of the drug over the gastrointestinal pH range in order to find the most suitable region of solubility and absorption. In this study, we are reporting saturated solubility of Osimertinib mesylate in different media with specific pH conditions including different physiological buffers such as simulated gastric fluid, simulated intestinal fluid, phosphate buffer saline. Solubility study was done by classical shake flask method and samples were analyzed by double beam UV spectrophotometer in triplicate. It was found to be very slightly soluble in water with an approximate value of 924 +/- 6.06 mu g/ml. Of all the tested buffer media, simulated gastric fluid pH 1.2, exhibited maximum solubility, which was approximately 2.3 folds of the solubility exhibited in distilled water. Solubility data over different pH conditions were statistically evaluated using one way ANOVA and post hoc Tukey test for valid conclusions. All media had significant effect on the solubility of the drug except sodium phosphate buffer, pH 3.2 and Acetate buffer pH 5.5 with respect to distilled water.
引用
收藏
页码:2610 / 2615
页数:6
相关论文
共 8 条
[1]   Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound [J].
Baka, Edit ;
Comer, John E. A. ;
Takacs-Novak, Krisztina .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 46 (02) :335-341
[2]   AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer [J].
Cross, Darren A. E. ;
Ashton, Susan E. ;
Ghiorghiu, Serban ;
Eberlein, Cath ;
Nebhan, Caroline A. ;
Spitzler, Paula J. ;
Orme, Jonathon P. ;
Finlay, M. Raymond V. ;
Ward, Richard A. ;
Mellor, Martine J. ;
Hughes, Gareth ;
Rahi, Amar ;
Jacobs, Vivien N. ;
Brewer, Monica Red ;
Ichihara, Eiki ;
Sun, Jing ;
Jin, Hailing ;
Ballard, Peter ;
Al-Kadhimi, Katherine ;
Rowlinson, Rachel ;
Klinowska, Teresa ;
Richmond, Graham H. P. ;
Cantarini, Mireille ;
Kim, Dong-Wan ;
Ranson, Malcolm R. ;
Pao, William .
CANCER DISCOVERY, 2014, 4 (09) :1046-1061
[3]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386
[4]   AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer [J].
Jaenne, Pasi A. ;
Yang, James Chih-Hsin ;
Kim, Dong-Wan ;
Planchard, David ;
Ohe, Yuichiro ;
Ramalingam, Suresh S. ;
Ahn, Myung-Ju ;
Kim, Sang-We ;
Su, Wu-Chou ;
Horn, Leora ;
Haggstrom, Daniel ;
Felip, Enriqueta ;
Kim, Joo-Hang ;
Frewer, Paul ;
Cantarini, Mireille ;
Brown, Kathryn H. ;
Dickinson, Paul A. ;
Ghiorghiu, Serban ;
Ranson, Malcolm .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) :1689-1699
[5]   Lung cancer chemoprevention: current status and future prospects [J].
Keith, Robert L. ;
Miller, York E. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (06) :334-343
[6]  
Lipinski C., 2002, AM PHARM REV, V5, P82
[7]   When poor solubility becomes an issue:: From early stage to proof of concept [J].
Stegemann, S. ;
Leveiller, F. ;
Franchi, D. ;
de Jong, H. ;
Linden, H. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 31 (05) :249-261
[8]  
Vishwanathan K, 2017, J CLIN PHARMACOL, P1